- Home
- XGN vs IKNA Comparison
XGN vs IKNA Comparison
Compare XGN & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- IKNA
- Stock Information
- Founded
- XGN 2002
- IKNA 2016
- Country
- XGN United States
- IKNA United States
- Employees
- XGN N/A
- IKNA N/A
- Industry
- XGN Medical Specialities
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- XGN Health Care
- IKNA Health Care
- Exchange
- XGN Nasdaq
- IKNA Nasdaq
- Market Cap
- XGN 72.3M
- IKNA 79.6M
- IPO Year
- XGN 2019
- IKNA 2021
- Fundamental
- Price
- XGN $5.65
- IKNA $1.59
- Analyst Decision
- XGN Buy
- IKNA Buy
- Analyst Count
- XGN 1
- IKNA 2
- Target Price
- XGN $7.00
- IKNA $3.00
- AVG Volume (30 Days)
- XGN 189.6K
- IKNA 99.7K
- Earning Date
- XGN 11-12-2024
- IKNA 11-07-2024
- Dividend Yield
- XGN N/A
- IKNA N/A
- EPS Growth
- XGN N/A
- IKNA N/A
- EPS
- XGN N/A
- IKNA N/A
- Revenue
- XGN $55,751,000.00
- IKNA $659,000.00
- Revenue This Year
- XGN $6.74
- IKNA N/A
- Revenue Next Year
- XGN $17.32
- IKNA N/A
- P/E Ratio
- XGN N/A
- IKNA N/A
- Revenue Growth
- XGN 8.00
- IKNA N/A
- 52 Week Low
- XGN $1.30
- IKNA $1.22
- 52 Week High
- XGN $6.22
- IKNA $2.30
- Technical
- Relative Strength Index (RSI)
- XGN 74.82
- IKNA 35.62
- Support Level
- XGN $5.60
- IKNA $1.56
- Resistance Level
- XGN $6.22
- IKNA $1.71
- Average True Range (ATR)
- XGN 0.48
- IKNA 0.05
- MACD
- XGN 0.13
- IKNA -0.01
- Stochastic Oscillator
- XGN 88.00
- IKNA 31.58
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.